Case-Controlhigh evidence
Respiratory Syncytial Virus-Related Hospitalizations Among Infants Receiving Nirsevimab.
JAMA network open·September 1, 2026·PMID 42734914
Why it mattersRSV is a leading cause of infant hospitalization, and nirsevimab is a newly funded universal prophylaxis in parts of Canada. These real-world effectiveness estimates support its use in reducing severe RSV outcomes, including ICU care, and can inform clinical decisions and public health policy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled